Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
20 July 2020 |
Main ID: |
EUCTR2012-002888-10-GB |
Date of registration:
|
24/09/2012 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A study to investigate the safety, tolerability and efficacy of PCI/Gemcitabine treatment followed by combination chemotherapy in patients with cholangiocarcinomas
|
Scientific title:
|
A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex®-induced Photochemical Internalisation (PCI) of Gemcitabine Followed by Gemcitabine/Cisplatin Chemotherapy in Patients with Advanced Inoperable Cholangiocarcinomas |
Date of first enrolment:
|
06/12/2012 |
Target sample size:
|
68 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002888-10 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: yes Other specify the comparator: PCI procedure + combination chemotherapy vs combination chemotherapy alone Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): yes
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Austria
|
France
|
Germany
|
Lithuania
|
Norway
|
United Kingdom
| | |
Contacts
|
Name:
|
Regulatory Affairs
|
Address:
|
2nd Floor, The Pinnacle, Station Way
RH10 1JH
Crawley
United Kingdom |
Telephone:
|
+4401293510319 |
Email:
|
regulatory@theradex.co.uk |
Affiliation:
|
Theradex (Europe) Ltd |
|
Name:
|
Regulatory Affairs
|
Address:
|
2nd Floor, The Pinnacle, Station Way
RH10 1JH
Crawley
United Kingdom |
Telephone:
|
+4401293510319 |
Email:
|
regulatory@theradex.co.uk |
Affiliation:
|
Theradex (Europe) Ltd |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Histopathologically/cytologically (C5) verified adenocarcinoma consistent with cholangiocarcinoma. 2. Cholangiocarcinoma that: A) Is considered to be inoperable B) Has a primary lesion in the perihilar biliary duct region that requires stent placement C) Has nodal enlargement =to N1 as per computed tomography/magnetic resonance imaging assessment D) If has metastatic disease, this should be confined to the liver parenchyma only 3. Adequate biliary drainage (either at least 50% of the liver volume, or at least two sectors), with no evidence of active uncontrolled infection (patients on antibiotics are eligible) 4. Age =18 years 5. The Eastern Cooperative Oncology Group performance status =1 6. Estimated life expectancy of at least 12 weeks 7. Written informed consent
Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 18 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 50
Exclusion criteria: 1. Any prior anti-cancer (either local or systemic) treatment for cholangiocarcinoma 2. Patients with extra-hepatic metastatic cholangiocarcinoma 3. Patients with a severe visceral disease other than cholangiocarcinoma. 4. Patients with primary sclerosing cholangitis 5. Patients with porphyria or hypersensibility to porphyrins 6. Patients with an active second primary cancer, with exception of adequately treated basal cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer, or in-situ carcinoma of the uterine cervix. An active second primary cancer is defined as one with a disease-free interval of <5 years before registration/randomisation. 7. Inability to undergo computed tomography or magnetic resonance imaging 8. Current participation in any other interventional clinical trial 9. Male patients not willing to use adequate contraception or female patients of childbearing potential not willing to use an effective form of contraception such as hormonal birth control, intrauterine device or double barrier method during PCI treatment and subsequent chemotherapy and for at least 6 months thereafter. 10. Breast feeding women or women with a positive pregnancy test at baseline 11. Inadequate bone marrow function: - Absolute neutrophil count: <1.5 x 109/L, or platelet count <100 x 109/L or haemoglobin <6 mmol/L (transfusion allowed) 12. Inadequate liver function, defined as: - Serum (total) bilirubin >2.5 x the upper limit of normal for the institution - Aspartate amino transferase or alanine amino transferase >3.0 x upper limit of normal (>5.0 x upper limit of normal if liver metastases are present) - Alkaline phosphatase levels >5.0 x upper limit of normal 13. Inadequate renal function, defined as: - Creatinine clearance <60 mL/min 14. Planned surgery, endoscopic examination or dental treatment in the first 30 days after PCI treatment 15. Co-existing ophthalmic disease likely to require slit-lamp examination within the first 90 days after PCI treatment 16. Clinically significant and uncontrolled cardiac disease including unstable angina, acute myocardial infarction within 6 months prior to baseline, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities and controlled and well treated chronic atrial fibrillation 17. Known allergy or sensitivity to photosensitisers 18. Ataxia telangiectasia 19. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, physical examination or laboratory findings) that may interfere with the planned PCI treatment, affect patient compliance or place the patient at high risk from treatment-related complications 20. Significant hearing impairment 21. Patients concurrently receiving phenytoin 22. Patients defined as vulnerable according to French law (France only, also see Section 5.4
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Inoperable advanced cholangiocarcinomas MedDRA version: 20.0
Level: LLT
Classification code 10008594
Term: Cholangiocarcinoma non-resectable
System Organ Class: 100000054936
|
Therapeutic area: Diseases [C] - Cancer [C04]
|
Intervention(s)
|
Product Name: Amphinex Pharmaceutical Form: Solution for injection INN or Proposed INN: fimaporfin CAS Number: 1443547-43-0 Current Sponsor code: TPCS2a Other descriptive name: AMPHINEX Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-
Product Name: Gemcitabine Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: GEMCITABINE CAS Number: 95058-81-4
|
Primary Outcome(s)
|
Timepoint(s) of evaluation of this end point: Please refer to study protocol
|
Main Objective: Phase I Dose Escalation • To determine a tolerable dose and safety profile of Amphinex-induced PCI of gemcitabine followed by systemic gemcitabine/cisplatin chemotherapy in patients with advanced inoperable cholangiocarcinoma
Extended Part of Phase I • To determine the tolerability and safety profile of a two-administration schedule of Amphinex-induced PCI of gemcitabine followed by systemic gemcitabine/cisplatin chemotherapy in patients with advanced inoperable cholangiocarcinoma
Phase II • To make a preliminary assessment of the efficacy of Amphinex-induced PCI of gemcitabine followed by systemic gemcitabine/cisplatin chemotherapy in patients with advanced inoperable cholangiocarcinoma
|
Primary end point(s): Phase I Dose Escalation (Safety) • Dose-limiting toxicities and the safety profile (adverse events, laboratory assessments and physical findings) of the Amphinex-induced PCI of gemcitabine followed by the gemcitabine/cisplatin combination
Extended Part of Phase I (Safety) • Schedule-limiting toxicities and the safety profile (adverse events, laboratory assessments and physical findings) of a two-administration schedule of Amphinex-induced PCI of gemcitabine followed by systemic gemcitabine/cisplatin chemotherapy
Phase II (Efficacy) • Progression-free survival, defined as the time from randomisation to documented disease progression (according to Response Evaluation Criteria in Solid Tumours [RECIST] 1.1 criteria) or death from any cause.
|
Secondary Objective: Phase I Dose Escalation • To characterise the pharmacokinetic profiles of Amphinex and gemcitabine • To make a preliminary assessment of the efficacy of Amphinex-induced PCI of gemcitabine followed by systemic gemcitabine/cisplatin chemotherapy in patients with advanced inoperable cholangiocarcinoma
Extended Part of Phase I • To characterise the pharmacokinetic profiles of Amphinex and gemcitabine • To make a preliminary assessment of the efficacy of a two-administration schedule of Amphinex-induced PCI of gemcitabine followed by systemic gemcitabine/cisplatin chemotherapy in patients with advanced inoperable cholangiocarcinoma
Phase II • To characterise the pharmacokinetic profile of Amphinex • To further assess the safety and efficacy profile of Amphinex-induced PCI of gemcitabine followed by the systemic gemcitabine/cisplatin combination
|
Secondary Outcome(s)
|
Secondary end point(s): Phase I Dose Escalation • Pharmacokinetic profile of Amphinex and gemcitabine in plasma • Progression-free survival, defined as the time from registration to documented disease progression (according to RECIST 1.1 criteria) or death from any cause • Best overall response
Extended Part of Phase I • Pharmacokinetic profile of Amphinex and gemcitabine in plasma • Progression-free survival, defined as the time from registration to documented disease progression (according to RECIST 1.1 criteria) or death from any cause • Best overall response at 24 weeks
Phase II • Overall response rate, calculated as the proportion of patients with a best overall response of confirmed complete response or partial response • Disease control rate, defined as the proportion of patients with best overall response of confirmed complete response, partial response or stable disease • Overall survival, calculated as the time from randomisation to the date of death from any cause • Best overall response • Pharmacokinetic profile of Amphinex in bile • Safety profile (adverse events, laboratory assessments and physical findings) of the Amphinex-induced PCI of gemcitabine followed by the gemcitabine/cisplatin combination, or the gemcitabine/cisplatin combination alone
|
Timepoint(s) of evaluation of this end point: Please refer to study protocol
|
Secondary ID(s)
|
PCIA202/12
|
Source(s) of Monetary Support
|
PCI Biotech AS
|
Ethics review
|
Status: Approved
Approval date: 06/12/2012
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|